1
|
Affiliation(s)
- Timothy J Wilt
- Minneapolis Veterans Affairs Health Care System, Minneapolis, MN
| | | | | |
Collapse
|
2
|
Krug U, Gale RP, Berdel WE, Müller-Tidow C, Stelljes M, Metzeler K, Sauerland MC, Hiddemann W, Büchner T. Therapy of older persons with acute myeloid leukaemia. Leuk Res 2017; 60:1-10. [PMID: 28618329 DOI: 10.1016/j.leukres.2017.05.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Revised: 05/24/2017] [Accepted: 05/27/2017] [Indexed: 12/20/2022]
Abstract
Most persons age≥60 y with acute myeloid leukaemia (AML) die from their disease. When interpreting clinical trials data from these persons one must be aware of substantial selection biases. Randomized trials of post-remission treatments can be performed upfront or after achieving defined landmarks. Both strategies have important limitations. Selection of the appropriate treatment is critical. Age, performance score, co-morbidities and frailty provide useful data to treatment selection. If an intensive remission induction therapy is appropriate, therapy with cytarabine and an anthracycline is the most common regimen. Non-intensive therapies consist of the hypo-methylating drugs azacitidine and decitabine, low-dose cytarabine and supportive care. Feasibility of doing an allotransplant in older persons with AML is increasing. However, only very few qualify. Results of cytogenetic testing are risk factor in young and old persons with AML. Adverse abnormalities are more frequent in older persons. Although data about the frequency of mutations in older persons with AML is increasing their prognostic impact is less clear than in younger subjects. Neither differences in the distribution of cytogenetic risk, mutations, nor differences in clinical risk factors between younger and older persons with AML completely explain the age-dependent outcome. Many drugs are in clinical development in older persons with AML. Their potential role in the treatment of older persons with AML remains to be defined.
Collapse
Affiliation(s)
- Utz Krug
- Klinikum Leverkusen, Department of Medicine 3, Am Gesundheitspark 11, 51375 Leverkusen, Germany.
| | - Robert Peter Gale
- Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
| | - Wolfgang E Berdel
- University Hospital Münster, Department of Medicine A, Albert-Schweitzer-Campus 1, Geb. A1, 48129 Münster, Germany.
| | - Carsten Müller-Tidow
- University Hospital Heidelberg, Department of Medicine V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
| | - Matthias Stelljes
- University Hospital Münster, Department of Medicine A, Albert-Schweitzer-Campus 1, Geb. A1, 48129 Münster, Germany.
| | - Klaus Metzeler
- University Hospital Großhadern, IIIrd Medical Department, Marchioninistraße 15, 81377 München, Germany.
| | - M Cristina Sauerland
- University of Münster, Institute of Biostatistics and Clinical Research, Schmeddingstr 56, 48149 Münster, Germany.
| | - Wolfgang Hiddemann
- University Hospital Großhadern, IIIrd Medical Department, Marchioninistraße 15, 81377 München, Germany.
| | - Thomas Büchner
- University Hospital Münster, Department of Medicine A, Albert-Schweitzer-Campus 1, Geb. A1, 48129 Münster, Germany
| |
Collapse
|
3
|
Eggener S. Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy. Eur Urol 2017; 71:515-516. [DOI: 10.1016/j.eururo.2016.09.049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2016] [Accepted: 09/30/2016] [Indexed: 11/26/2022]
|
4
|
Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, Stabenow R, Froehner M, Huber J. Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011. Radiother Oncol 2015; 115:90-5. [DOI: 10.1016/j.radonc.2015.02.024] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2014] [Revised: 02/19/2015] [Accepted: 02/26/2015] [Indexed: 10/23/2022]
|